Oscotec Inc Total Liabilities
Oscotec Inc total liabilities. Based on the latest financial reports, Oscotec Inc (039200) has total liabilities worth ₩43.06 Billion KRW (≈ $29.18 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 039200 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oscotec Inc (2011–2025)
Total liabilities of Oscotec Inc from 2011 to 2025. This chart illustrates how Oscotec Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 039200 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Oscotec Inc Competitors by Total Liabilities
The table below lists competitors of Oscotec Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dark Horse Beijing Technology Co Ltd
SHE:300688
|
China | CN¥157.33 Million |
|
Naphtha
TA:NFTA
|
Israel | ILA3.16 Billion |
|
Risesun Real Estate Development Co Ltd
SHE:002146
|
China | CN¥117.05 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥4.36 Billion |
|
Sabre Corpo
NASDAQ:SABR
|
USA | $5.43 Billion |
|
Liaoning Oxiranchem Inc
SHE:300082
|
China | CN¥3.09 Billion |
|
AEVEX Corp.
NYSE:AVEX
|
USA | $384.19 Million |
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
USA | $1.62 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Oscotec Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Oscotec Inc.
Liquidity & Leverage Metrics
Oscotec Inc Total Liabilities Ratios Explained
Oscotec Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oscotec Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oscotec Inc (2011–2025)
The table below shows the annual total liabilities of Oscotec Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩43.01 Billion ≈ $29.14 Million |
+11.94% |
| 2024-12-31 | ₩38.42 Billion ≈ $26.04 Million |
+1.47% |
| 2023-12-31 | ₩37.86 Billion ≈ $25.66 Million |
+78.36% |
| 2022-12-31 | ₩21.23 Billion ≈ $14.39 Million |
+5.40% |
| 2021-12-31 | ₩20.14 Billion ≈ $13.65 Million |
-13.70% |
| 2020-12-31 | ₩23.34 Billion ≈ $15.82 Million |
+10.58% |
| 2019-12-31 | ₩21.11 Billion ≈ $14.30 Million |
-11.95% |
| 2018-12-31 | ₩23.97 Billion ≈ $16.24 Million |
+24.17% |
| 2017-12-31 | ₩19.30 Billion ≈ $13.08 Million |
+33.23% |
| 2016-12-31 | ₩14.49 Billion ≈ $9.82 Million |
-35.84% |
| 2015-12-31 | ₩22.58 Billion ≈ $15.30 Million |
+55.88% |
| 2014-12-31 | ₩14.49 Billion ≈ $9.82 Million |
-6.44% |
| 2013-12-31 | ₩15.48 Billion ≈ $10.49 Million |
-16.66% |
| 2012-12-31 | ₩18.58 Billion ≈ $12.59 Million |
-16.50% |
| 2011-12-31 | ₩22.25 Billion ≈ $15.08 Million |
-- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more